Ligustilide alleviates hepatic fibrosis by targeting the mesenchymal homeobox 1 (MEOX1)– transcriptional enhanced associate domain factor 2 (TEAD2) signalling axis
British Journal of Pharmacology · 2026-08 · 183 (16) · 4818-4835
DOI: 10.1111/bph.70499 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 12.05.2026. Verfasst von Qinrong Luan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: 4-Butyrolactone, Liver Cirrhosis, Transcription Factors, Homeodomain Proteins. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Youth Talent Cultivation Fund Project of Dalian Medical University.
Abstract (Originalsprache)
Background and Purpose Mesenchyme homeobox 1 (MEOX1) has been characterised as a central transcriptional regulator of fibroblast activation. Ligustilide (LIG) has significant antifibrotic, anti‐inflammatory and antioxidative activities. We investigated if LIG can ameliorate hepatic fibrosis by targeting MEOX1 and exploring the underlying mechanism. Experimental Approach In vivo, carbon tetrachloride (CCl 4 )‐induced mice were used to assess the antifibrotic effects of AAV9–pGFAP–sh–MEOX1 and LIG. In vitro, LX‐2 cells, following transfection with siRNA or pcDNA or pretreatment with LIG, were incubated with TGF‐ β 1 for the assessment. Key Results Knockdown of MEOX1 mitigated fibrosis, both in vivo and in vitro. Furthermore, through a strategy involving Traditional Chinese Medicine (TCM) prescription screening, molecular docking, cellular thermal shift assay (CETSA), site‐specific mutation and surface plasmon resonance (SPR), we identified LIG as a potential inhibitor of MEOX1. Subsequent validation confirmed that LIG exerted significant antifibrotic effects through MEOX1. Mechanistic studies revealed that MEOX1 promoted transcriptional enhanced associate domain factor 2 (TEAD2) transcription, by binding to the −988 to −982 nt region of the TEAD2 promoter, which increased the transcription of Hippo signalling targets and stimulated hepatic stellate cell (HSC) activation and proliferation. LIG can also bind to the HOX domain of MEOX1, thereby inhibiting its function and alleviating hepatic fibrosis. Conclusion and Implications The MEOX1–TEAD2 signalling axis is crucial for hepatic fibrosis. LIG attenuates hepatic fibrosis by targeting MEOX1 and inhibiting the downstream of the Hippo signalling pathway. Our results elucidated the mechanistic basis for developing LIG as a clinical antifibrotic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Dalian Medical University, Dalian, China.
- Department of Basic Medical Sciences, Dalian Medical University, Dalian, China.
- Department of Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
ORCID-Profile: Jihong Yao
Förderung
- Youth Talent Cultivation Fund Project of Dalian Medical University
Zitieren
APA
Luan, Q., Wang, Z., Wang, Y., Xu, J., Wang, G., Hu, Z., Zhou, J., Tian, X., Zhao, Y., & Yao, J. (2026). Ligustilide alleviates hepatic fibrosis by targeting the mesenchymal homeobox 1 (MEOX1)– transcriptional enhanced associate domain factor 2 (TEAD2) signalling axis. British Journal of Pharmacology, 183(16), 4818-4835. https://doi.org/10.1111/bph.70499
Vancouver
Luan Q, Wang Z, Wang Y, Xu J, Wang G, Hu Z, et al. Ligustilide alleviates hepatic fibrosis by targeting the mesenchymal homeobox 1 (MEOX1)– transcriptional enhanced associate domain factor 2 (TEAD2) signalling axis. British Journal of Pharmacology. 2026;183(16):4818-4835. doi:10.1111/bph.70499
BibTeX
@article{Luan2026,
author = {Luan, Qinrong and Wang, Zhecheng and Wang, Yue and Xu, Jiali and Wang, Guorong and Hu, Zhehao and Zhou, Junjun and Tian, Xiaofeng and Zhao, Yan and Yao, Jihong},
title = {Ligustilide alleviates hepatic fibrosis by targeting the mesenchymal homeobox 1 (MEOX1)– transcriptional enhanced associate domain factor 2 (TEAD2) signalling axis},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {16},
pages = {4818--4835},
doi = {10.1111/bph.70499}
}
EUVIMED